Search clinical trials for: BI 144807 intermediate dose

Total 147 results

Rajaie Cardiovascular Medical and Research Center
Brigham and Women's Hospital; Tehran Heart Center; Imam Khomeini Hospital; Masih... and other collaborators

Completed

Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 (INSPIRATION)

Covid19

Iran, Islamic Republic of
Boehringer Ingelheim

Terminated

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

BI 44370 TA in Acute Migraine Attack

Migraine Disorders

Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
National Taiwan University Hospital

Completed

Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection

Hepatitis

Taiwan
Marijn Lijffijt, PhD
Michael E. DeBakey VA Medical Center; VistaGen Therapeutics, Inc.

Completed

Electrophysiological Biomarkers of AV-101

Healthy

United States
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Healthy
Columbia University

Completed

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (IMPROVE)

COVID-19 | Venous Thromboses | Arterial Thrombosis

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan; Q-Pharm Pty...

Completed

Safety and Blood Level Study of Unit Dose Budesonide (UDB P101)

Asthma

Australia
Sirtris, a GSK Company

Completed

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Psoriasis

United States
University Hospital, Strasbourg, France

Terminated

Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women

Oxidative Stress | Gestational Diabetes | Treatment | Metformin

France
Boehringer Ingelheim

Terminated

Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN)

Heart Valve Diseases

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
Boehringer Ingelheim

Terminated

Follow on Study From RE-ALIGN

Thromboembolism | Heart Valve Prosthesis

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers

Healthy

Germany
wang, jianxiang

Recruiting

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | CEBPA Double Mutation

China
Northwell Health

Completed

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

COVID | Sars-CoV2

United States
Boehringer Ingelheim

Completed

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Celgene

Completed

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY)

Leukemia, Myeloid | Isocitrate Dehydrogenase

United States, Canada, China, Czechia, France, Germany, Italy, United Kingdom, Australia, Austria, Brazil, Denmark, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, Belgium
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Healthy

Germany
Menarini Group

Completed

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee (ALBATROSS-3)

Knee Osteoarthritis

United States, Italy, Germany, Czech Republic
French Innovative Leukemia Organisation

Completed

Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

Acute Myeloid Leukemia

France
Boehringer Ingelheim

Completed

BI 671800 ED in Steroid-naive Asthmatic Patients

Asthma

United States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Healthy
Incyte Corporation

Terminated

Study of INCB053914 in Subjects With Advanced Malignancies

Solid Tumors

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
Boehringer Ingelheim

Completed

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy
Pfizer

Recruiting

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Healthy Participants

United States
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Alan Barkun
Pendopharm

Completed

The Bowel CLEAnsing: A National Initiative (B-CLEAN)

Subjets Requiring a Colonoscopy

Canada
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
MorphoSys AG
Clinigen Healthcare Ltd

Approved for marketing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

DLBCL
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

AML

China
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Assistance Publique - Hôpitaux de Paris
Novartis

Completed

Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome (MSN)

Nephrotic Syndrome

France

3

Subscribe